Can peripheral leukocytes be used as Alzheimer’s disease biomarkers?

References

• Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev.81(2), 741–766 (2001).
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol.60(8), 1119–1122 (2003).
   PubMed Web of Science ®Google Scholar
• Plassman BL, Langa KM, Fisher GG et al. Prevalence of dementia in the United States: the Aging, Demographics, and Memory study. Neuroepidemiology29(1–2), 125–132 (2007).
   PubMed Web of Science ®Google Scholar
• Brookmeyer R, Gray S, Kawas C. Projections of Alzheimers-disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health88(9), 1337–1342 (1998).
   PubMed Web of Science ®Google Scholar
• Petersen RC. Challenges of epidemiological studies of mild cognitive impairment. Alzheimer Dis. Assoc. Disord.18(1), 1–2 (2004).
   PubMed Web of Science ®Google Scholar
• Tanzi RE. Alzheimer’s disease and related dementias: the road to intervention. Exp. Gerontol.35(4), 433–437 (2000).
   Google Scholar
• Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. Sci.12(10), 383–388 (1991).
   PubMed Web of Science ®Google Scholar
• Sipe JD, Cohen AS. Review: history of the amyloid fibril. J. Struct. Biol.130(2–3), 88–98 (2000).
   PubMed Web of Science ®Google Scholar
• Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-β oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans.30(4), 552–557 (2002).
   PubMed Web of Science ®Google Scholar
• Benzing WC, Wujek JR, Ward EK et al. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol. Aging20(6), 581–589 (1999).
   PubMed Web of Science ®Google Scholar
• McGowan E, Sanders S, Iwatsubo T et al. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol. Dis.6(4), 231–244 (1999).
   Google Scholar
• McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease. Exp. Gerontol.33(5), 371–378 (1998).
   PubMed Web of Science ®Google Scholar
• McGeer EG, McGeer PL. Inflammatory processes in Alzheimer’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry27(5), 741–749 (2003).
   PubMed Web of Science ®Google Scholar
• Akiyama H, Barger S, Barnum S et al. Inflammation and Alzheimer’s disease. Neurobiol. Aging21(3), 383–421 (2000).
   PubMed Web of Science ®Google Scholar
• Tan J, Town T, Paris D et al. Microglial activation resulting from CD40–CD40L interaction after β-amyloid stimulation. Science286(5448), 2352–2355 (1999).
   PubMed Web of Science ®Google Scholar
• Tan J, Town T, Mullan M. CD40–CD40L interaction in Alzheimer’s disease. Curr. Opin. Pharmacol.2(4), 445–451 (2002).
   Google Scholar
• Tan J, Town T, Crawford F et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer’s mice. Nat. Neurosci.5(12), 1288–1293 (2002).
   PubMed Web of Science ®Google Scholar
• Town T, Tan J, Mullan M. CD40 signaling and Alzheimer’s disease pathogenesis. Neurochem. Int.39(5–6), 371–380 (2001).
   PubMedGoogle Scholar
• Town T, Nikolic V, Tan J. The microglial ‘activation’ continuum: from innate to adaptive responses. J. Neuroinflammation2, 24 (2005).
   PubMed Web of Science ®Google Scholar
• Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease a double-edged sword. Neuron35(3), 419–432 (2002).
   PubMed Web of Science ®Google Scholar
• in t’ Veld BA, Ruitenberg A, Hofman A et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N. Engl. J. Med.345(21), 1515–1521 (2001).
   PubMed Web of Science ®Google Scholar
• Szekely CA, Thorne JE, Zandi PP et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease: a systematic review. Neuroepidemiology23(4), 159–169 (2004).
   PubMed Web of Science ®Google Scholar
• Szekely CA, Town T, Zandi PP. NSAIDs for the chemoprevention of Alzheimer’s disease. Subcell. Biochem.42, 229–248 (2007).
   PubMedGoogle Scholar
• McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology47(2), 425–432 (1996).
   PubMed Web of Science ®Google Scholar
• Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County study. Neurology59(6), 880–886 (2002).
   PubMed Web of Science ®Google Scholar
• Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology48(3), 626–632 (1997).
   PubMed Web of Science ®Google Scholar
• Cornelius C, Fastbom J, Winblad B, Viitanen M. Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology23(3), 135–143 (2004).
   PubMed Web of Science ®Google Scholar
• Szekely CA, Breitner JC, Fitzpatrick AL et al. NSAID use and dementia risk in the Cardiovascular Health study: role of APOE and NSAID type. Neurology70(1), 17–24 (2008).
   PubMed Web of Science ®Google Scholar
• Breitner JC, Haneuse SJ, Walker R et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology72(22), 1899–1905 (2009).
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Grodstein F, Bienias JL et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology70(23), 2219–2225 (2008).
   PubMed Web of Science ®Google Scholar
• Reines SA, Block GA, Morris JC et al. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology62(1), 66–71 (2004).
   PubMed Web of Science ®Google Scholar
• Rogers J, Kirby LC, Hempelman SR et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology43(8), 1609–1611 (1993).
   PubMed Web of Science ®Google Scholar
• Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology53(1), 197–201 (1999).
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer’s disease. Neurology58(7), 1050–1054 (2002).
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA289(21), 2819–2826 (2003).
   PubMed Web of Science ®Google Scholar
• Thal LJ, Ferris SH, Kirby L et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology30(6), 1204–1215 (2005).
   PubMed Web of Science ®Google Scholar
• ADAPT Research Group, Lyketsos CG, Breitner JC et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology68(21), 1800–1808 (2007).
   PubMed Web of Science ®Google Scholar
• Franceschi C, Capri M, Monti D et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech. Ageing Dev.128(1), 92–105 (2007).
   PubMed Web of Science ®Google Scholar
• Giunta B, Fernandez F, Nikolic WV et al. Inflammaging as a prodrome to Alzheimer’s disease. J. Neuroinflammation5, 51 (2008).
   PubMed Web of Science ®Google Scholar
• Town T, Tan J, Flavell RA, Mullan M. T-cells in Alzheimer’s disease. Neuromolecular Med.7(3), 255–264 (2005).
   PubMedGoogle Scholar
• Flurkey K, Stadecker M, Miller RA. Memory T lymphocyte hyporesponsiveness to non-cognate stimuli: a key factor in age-related immunodeficiency. Eur. J. Immunol.22(4), 931–935 (1992).
   Google Scholar
• Monsonego A, Zota V, Karni A et al. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J. Clin. Invest.112(3), 415–422 (2003).
   PubMed Web of Science ®Google Scholar
• Dutton RW, Bradley LM, Swain SL. T cell memory. Annu. Rev. Immunol.16, 201–223 (1998).
   PubMed Web of Science ®Google Scholar
• Tan J, Town T, Abdullah L et al. CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer’s disease. J. Neuroimmunol.132(1–2), 164–172 (2002).
   PubMed Web of Science ®Google Scholar
• Burke JR, Roses AD. Genetics of Alzheimer’s disease. Int. J. Neurol.25–26, 41–51 (1991).
   Google Scholar
• Mayeux R, Stern Y, Ottman R et al. The apolipoprotein epsilon 4 allele in patients with Alzheimer’s disease. Ann. Neurol.34(5), 752–754 (1993).
   PubMed Web of Science ®Google Scholar
• Roses AD. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer’s disease. Ann. Neurol.38(1), 6–14 (1995).
   PubMed Web of Science ®Google Scholar
• Roses AD. Genetic testing and Alzheimer disease: the promise. Alzheimer Dis. Assoc. Disord.12(Suppl. 3), S3–S9 (1998).
   Google Scholar
• Larbi A, Pawelec G, Witkowski JM et al. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer’s disease. J. Alzheimers Dis.17(1), 91–103 (2009).
   PubMed Web of Science ®Google Scholar
• Jago CB, Yates J, Camara NO, Lechler RI, Lombardi G. Differential expression of CTLA-4 among T cell subsets. Clin. Exp. Immunol.136(3), 463–471 (2004).
   PubMed Web of Science ®Google Scholar
• Itagaki S, McGeer PL, Akiyama H. Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer’s disease brain tissue. Neurosci. Lett.91(3), 259–264 (1988).
   PubMed Web of Science ®Google Scholar
• Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer’s disease. Neurobiol. Aging9(4), 339–349 (1988).
   PubMed Web of Science ®Google Scholar
• Togo T, Akiyama H, Iseki E et al. Occurrence of T cells in the brain of Alzheimer’s disease and other neurological diseases. J. Neuroimmunol.124(1–2), 83–92 (2002).
   PubMed Web of Science ®Google Scholar
• Pirttila T, Mattinen S, Frey H. The decrease of CD8-positive lymphocytes in Alzheimer’s disease. J. Neurol. Sci.107(2), 160–165 (1992).
   PubMed Web of Science ®Google Scholar
• Skias D, Bania M, Reder AT, Luchins D, Antel JP. Senile dementia of Alzheimer’s type (SDAT): reduced T8+-cell-mediated suppressor activity. Neurology35(11), 1635–1638 (1985).
   PubMedGoogle Scholar
• Shalit F, Sredni B, Brodie C, Kott E, Huberman M. T lymphocyte subpopulations and activation markers correlate with severity of Alzheimer’s disease. Clin. Immunol. Immunopathol.75(3), 246–250 (1995).
   PubMedGoogle Scholar
• Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V, Baloyannis S. Systemic immune aberrations in Alzheimer’s disease patients. J. Neuroimmunol.193(1–2), 183–187 (2008).
   PubMed Web of Science ®Google Scholar
• Leffell MS, Lumsden L, Steiger WA. An analysis of T lymphocyte subpopulations in patients with Alzheimer’s disease. J. Am. Geriatr. Soc.33(1), 4–8 (1985).
   PubMedGoogle Scholar
• Singh VK. Neuroimmune axis as a basis of therapy in Alzheimer’s disease. Prog. Drug Res.34, 383–393 (1990).
   Google Scholar
• Ikeda T, Yamamoto K, Takahashi K, Yamada M. Immune system-associated antigens on the surface of peripheral blood lymphocytes in patients with Alzheimer’s disease. Acta Psychiatr. Scand.83(6), 444–448 (1991).
   PubMedGoogle Scholar
• Richartz-Salzburger E, Batra A, Stransky E et al. Altered lymphocyte distribution in Alzheimer’s disease. J. Psychiatr. Res.41(1–2), 174–178 (2007).
   Google Scholar
• Hu GR, Walls RS, Creasey H, McCusker E, Broe GA. Peripheral blood lymphocyte subset distribution and function in patients with Alzheimer’s disease and other dementias. Aust. NZ J. Med.25(3), 212–217 (1995).
   Google Scholar
• Chen K, Huang J, Gong W, Zhang L, Yu P, Wang JM. CD40/CD40L dyad in the inflammatory and immune responses in the central nervous system. Cell. Mol. Immunol.3(3), 163–169 (2006).
   PubMed Web of Science ®Google Scholar
• Abdel-Haq N, Hao HN, Lyman WD. Cytokine regulation of CD40 expression in fetal human astrocyte cultures. J. Neuroimmunol.101(1), 7–14 (1999).
   Google Scholar
• Tan J, Town T, Mori T et al. CD40 is expressed and functional on neuronal cells. EMBO J.21(4), 643–652 (2002).
   Google Scholar
• Togo T, Akiyama H, Kondo H et al. Expression of CD40 in the brain of Alzheimer’s disease and other neurological diseases. Brain Res.885(1), 117–121 (2000).
   PubMedGoogle Scholar
• Townsend KP, Town T, Mori T et al. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid β-peptide. Eur. J. Immunol.35(3), 901–910 (2005).
   PubMed Web of Science ®Google Scholar
• Tan J, Town T, Suo Z et al. Induction of CD40 on human endothelial cells by Alzheimer’s β-amyloid peptides. Brain Res. Bull.50(2), 143–148 (1999).
   Google Scholar
• Tan J, Town T, Paris D et al. Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis. J. Neuroimmunol.97(1–2), 77–85 (1999).
   Google Scholar
• Aloisi F, Ria F, Penna G, Adorini L. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J. Immunol.160(10), 4671–4680 (1998).
   PubMed Web of Science ®Google Scholar
• Calingasan NY, Erdely HA, Altar CA. Identification of CD40 ligand in Alzheimer’s disease and in animal models of Alzheimer’s disease and brain injury. Neurobiol. Aging23(1), 31–39 (2002).
   Google Scholar
• van Kooten C, Banchereau J. CD40–CD40 ligand. J. Leukoc. Biol.67(1), 2–17 (2000).
   PubMed Web of Science ®Google Scholar
• Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol.16, 111–135 (1998).
   PubMed Web of Science ®Google Scholar
• Grewal IS, Foellmer HG, Grewal KD et al. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science273(5283), 1864–1867 (1996).
   PubMed Web of Science ®Google Scholar
• Obradovic SD, Antovic JP, Antonijevic NM et al. Elevations in soluble CD40 ligand in patients with high platelet aggregability undergoing percutaneous coronary intervention. Blood Coagul. Fibrinolysis20(4), 283–289 (2009).
   PubMed Web of Science ®Google Scholar
• Lessiani G, Dragani A, Falco A, Fioritoni F, Santilli F, Davi G. Soluble CD40 ligand and endothelial dysfunction in aspirin-treated polycythaemia vera patients. Br. J. Haematol.145(4), 538–540 (2009).
   PubMed Web of Science ®Google Scholar
• Mocali A, Cedrola S, Della Malva N et al. Increased plasma levels of soluble CD40, together with the decrease of TGF β 1, as possible differential markers of Alzheimer disease. Exp. Gerontol.39(10), 1555–1561 (2004).
   PubMed Web of Science ®Google Scholar
• Holcomb L, Gordon MN, McGowan E et al. Accelerated alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med.4(1), 97–100 (1998).
   PubMed Web of Science ®Google Scholar
• Todd Roach J, Volmar CH, Dwivedi S et al. Behavioral effects of CD40–CD40L pathway disruption in aged PSAPP mice. Brain Res.1015(1–2), 161–168 (2004).
   PubMed Web of Science ®Google Scholar
• Desideri G, Cipollone F, Necozione S et al. Enhanced soluble CD40 ligand and Alzheimer’s disease: evidence of a possible pathogenetic role. Neurobiol. Aging29(3), 348–356 (2008).
   PubMed Web of Science ®Google Scholar
• Giunta B, Figueroa KP, Town T, Tan J. Soluble CD40 ligand in dementia. Drugs Future34(4), 333–339 (2009).
   Google Scholar
• Harman D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol.11(3), 298–300 (1956).
   PubMedGoogle Scholar
• Harman D. Origin and evolution of the free radical theory of aging: a brief personal history, 1954–2009. Biogerontology (2009).
   Google Scholar
• Smith MA, Kutty RK, Richey PL et al. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer’s disease. Am. J. Pathol.145(1), 42–47 (1994).
   PubMed Web of Science ®Google Scholar
• Smith MA, Tabaton M, Perry G. Early contribution of oxidative glycation in Alzheimer disease. Neurosci. Lett.217(2–3), 210–211 (1996).
   Google Scholar
• Eckert A, Cotman CW, Zerfass R, Hennerici M, Muller WE. Lymphocytes as cell model to study apoptosis in Alzheimer’s disease: vulnerability to programmed cell death appears to be altered. J. Neural. Transm. Suppl.54, 259–267 (1998).
   PubMedGoogle Scholar
• Schindowski K, Leutner S, Muller WE, Eckert A. Age-related changes of apoptotic cell death in human lymphocytes. Neurobiol. Aging21(5), 661–670 (2000).
   PubMedGoogle Scholar
• Eckert A, Schindowski K, Leutner S et al. Alzheimer’s disease-like alterations in peripheral cells from presenilin-1 transgenic mice. Neurobiol. Dis.8(2), 331–342 (2001).
   PubMed Web of Science ®Google Scholar
• Sulger J, Dumais-Huber C, Zerfass R, Henn FA, Aldenhoff JB. The calcium response of human T lymphocytes is decreased in aging but increased in Alzheimer’s dementia. Biol. Psychiatry45(6), 737–742 (1999).
   Google Scholar
• Richartz E, Noda S, Schott K, Gunthner A, Lewczuk P, Bartels M. Increased serum levels of CD95 in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.13(3), 178–182 (2002).
   Google Scholar
• Lombardi VR, Garcia M, Rey L, Cacabelos R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer’s disease (AD) individuals. J. Neuroimmunol.97(1–2), 163–171 (1999).
   PubMed Web of Science ®Google Scholar
• Tavolato B, Argentiero V. Immunological indices in presenile Alzheimer’s disease. J. Neurol. Sci.46(3), 325–331 (1980).
   PubMedGoogle Scholar
• Tollefson GD, Godes M, Warren JB, Haus E, Luxenberg M, Garvey M. Lymphopenia in primary degenerative dementia. J. Psychiatr. Res.23(3–4), 191–199 (1989).
   Google Scholar
• Dysken MW, Minichiello MD, Hill JL et al. Distribution of peripheral lymphocytes in Alzheimer patients and controls. J. Psychiatr. Res.26(3), 213–218 (1992).
   PubMedGoogle Scholar
• Magaki S, Yellon SM, Mueller C, Kirsch WM. Immunophenotypes in the circulation of patients with mild cognitive impairment. J. Psychiatr. Res.42(3), 240–246 (2008).
   PubMed Web of Science ®Google Scholar
• Bullido MJ, Munoz-Fernandez MA, Recuero M, Fresno M, Valdivieso F. Alzheimer’s amyloid precursor protein is expressed on the surface of hematopoietic cells upon activation. Biochim. Biophys. Acta1313(1), 54–62 (1996).
   Google Scholar
• Pallister C, Jung SS, Shaw I, Nalbantoglu J, Gauthier S, Cashman NR. Lymphocyte content of amyloid precursor protein is increased in Down’s syndrome and aging. Neurobiol. Aging18(1), 97–103 (1997).
   Google Scholar
• Jung SS, Gauthier S, Cashman NR. β-amyloid precursor protein is detectable on monocytes and is increased in Alzheimer’s disease. Neurobiol. Aging20(3), 249–257 (1999).
   Google Scholar
• Stieler JT, Lederer C, Bruckner MK et al. Impairment of mitogenic activation of peripheral blood lymphocytes in Alzheimer’s disease. Neuroreport12(18), 3969–3972 (2001).
   Google Scholar
• Lopez OL, Rabin BS, Huff FJ. Serum auto-antibodies in Alzheimer’s disease. Acta Neurol. Scand.84(5), 441–444 (1991).
   PubMedGoogle Scholar
• Du Y, Dodel R, Hampel H et al. Reduced levels of amyloid β-peptide antibody in Alzheimer disease. Neurology57(5), 801–805 (2001).
   PubMed Web of Science ®Google Scholar
• Hyman BT, Smith C, Buldyrev I et al. Autoantibodies to amyloid-β and Alzheimer’s disease. Ann. Neurol.49(6), 808–810 (2001).
   PubMed Web of Science ®Google Scholar
• Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol.37(7), 943–948 (2002).
   PubMed Web of Science ®Google Scholar
• Brettschneider S, Morgenthaler NG, Teipel SJ et al. Decreased serum amyloid β(1–42) autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β(1–42) peptide. Biol. Psychiatry57(7), 813–816 (2005).
   PubMed Web of Science ®Google Scholar
• Baril L, Nicolas L, Croisile B et al. Immune response to Aβ-peptides in peripheral blood from patients with Alzheimer’s disease and control subjects. Neurosci. Lett.355(3), 226–230 (2004).
   Google Scholar
• Nath A, Hall E, Tuzova M et al. Autoantibodies to amyloid β-peptide (Aβ) are increased in Alzheimer’s disease patients and Aβ antibodies can enhance Aβ neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med.3(1), 29–39 (2003).
   PubMed Web of Science ®Google Scholar
• Gruden MA, Davudova TB, Malisauskas M et al. Autoimmune responses to amyloid structures of Aβ(25–35) peptide and human lysozyme in the serum of patients with progressive Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.18(2), 165–171 (2004).
   Google Scholar
• Mruthinti S, Buccafusco JJ, Hill WD et al. Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Aβ and RAGE peptides. Neurobiol. Aging25(8), 1023–1032 (2004).
   PubMed Web of Science ®Google Scholar
• Wilson JS, Mruthinti S, Buccafusco JJ et al. Anti-RAGE and Aβ immunoglobulin levels are related to dementia level and cognitive performance. J. Gerontol. A. Biol. Sci. Med. Sci.64(2), 264–271 (2009).
   PubMed Web of Science ®Google Scholar
• Myagkova MA, Gavrilova SI, Lermontova NN et al. Content of autoantibodies to bradykinin and β-amyloid(1–42) as a criterion for biochemical differences between Alzheimer’s dementias. Bull. Exp. Biol. Med.136(1), 49–52 (2003).
   Google Scholar
• Britschgi M, Olin CE, Johns HT et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease. Proc. Natl Acad. Sci. USA106(29), 12145–12150 (2009).
   PubMed Web of Science ®Google Scholar
• Moir RD, Tseitlin KA, Soscia S, Hyman BT, Irizarry MC, Tanzi RE. Autoantibodies to redox-modified oligomeric Aβ are attenuated in the plasma of Alzheimer’s disease patients. J. Biol. Chem.280(17), 17458–17463 (2005).
   PubMed Web of Science ®Google Scholar
• Sun JC, Lanier LL. Natural killer cells remember: an evolutionary bridge between innate and adaptive immunity? Eur. J. Immunol.39(8), 2059–2064 (2009).
   Google Scholar
• Araga S, Kagimoto H, Funamoto K, Takahashi K. Reduced natural killer cell activity in patients with dementia of the Alzheimer type. Acta Neurol. Scand.84(3), 259–263 (1991).
   PubMedGoogle Scholar
• Solerte SB, Fioravanti M, Severgnini S et al. Enhanced cytotoxic response of natural killer cells to interleukin-2 in Alzheimer’s disease. Dementia7(6), 343–348 (1996).
   Google Scholar
• Masera RG, Prolo P, Sartori ML et al. Mental deterioration correlates with response of natural killer (NK) cell activity to physiological modifiers in patients with short history of Alzheimer’s disease. Psychoneuroendocrinology27(4), 447–461 (2002).
   Google Scholar
• Prolo P, Chiappelli F, Angeli A et al. Physiologic modulation of natural killer cell activity as an index of Alzheimer’s disease progression. Bioinformation1(9), 363–366 (2007).
   Google Scholar
• Leblhuber F, Walli J, Demel U, Tilz GP, Widner B, Fuchs D. Increased serum neopterin concentrations in patients with Alzheimer’s disease. Clin. Chem. Lab. Med.37(4), 429–431 (1999).
   Google Scholar
• Murr C, Fuith LC, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res.19(3A), 1721–1728 (1999).
   PubMed Web of Science ®Google Scholar
• Hull M, Pasinetti GM, Aisen PS. Elevated plasma neopterin levels in Alzheimer disease. Alzheimer Dis. Assoc. Disord.14(4), 228–230 (2000).
   PubMed Web of Science ®Google Scholar
• Zhang L, Fiala M, Cashman J et al. Curcuminoids enhance amyloid-β uptake by macrophages of Alzheimer’s disease patients. J. Alzheimers Dis.10(1), 1–7 (2006).
   PubMed Web of Science ®Google Scholar
• Town T, Laouar Y, Pittenger C et al. Blocking TGF-β-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med.14(6), 681–687 (2008).
   PubMed Web of Science ®Google Scholar
• Town T. Alternative Aβ immunotherapy approaches for Alzheimer’s disease. CNS Neurol. Disord. Drug Targets8(2), 114–127 (2009).
   PubMed Web of Science ®Google Scholar
• Rezai-Zadeh K, Gate D, Town T. CNS infiltration of peripheral macrophages: D-day for neurodegenerative disease? J. Neuroimmune Pharmacol. (2009) (In press).
   Google Scholar
• Avagyan H, Goldenson B, Tse E et al. Immune blood biomarkers of Alzheimer disease patients. J. Neuroimmunol.210(1–2), 67–72 (2009).
   Google Scholar
• Fiala M, Liu PT, Espinosa-Jeffrey A et al. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer’s disease patients are improved by bisdemethoxycurcumin. Proc. Natl Acad. Sci. USA104(31), 12849–12854 (2007).
   PubMed Web of Science ®Google Scholar
• Kusdra L, Rempel H, Yaffe K, Pulliam L. Elevation of CD69+ monocyte/macrophages in patients with Alzheimer’s disease. Immunobiology202(1), 26–33 (2000).
   Google Scholar
• Song C, Vandewoude M, Stevens W et al. Alterations in immune functions during normal aging and Alzheimer’s disease. Psychiatry Res.85(1), 71–80 (1999).
   Google Scholar
• Licastro F, Morini MC, Davis LJ et al. Increased chemiluminescence response of neutrophils from the peripheral blood of patients with senile dementia of the Alzheimer’s type. J. Neuroimmunol.51(1), 21–26 (1994).
   Google Scholar
• Scali C, Prosperi C, Bracco L et al. Neutrophils CD11b and fibroblasts PGE(2) are elevated in Alzheimer’s disease. Neurobiol. Aging23(4), 523–530 (2002).
   PubMed Web of Science ®Google Scholar
• Koltringer P, Reiseeker F, Eber O, Langsteger W, Lind P. The rheology of erythrocytes and granulocytes in Alzheimer’s disease and multi-infarction-dementia: a prospective study. J. Neural. Trasm.1, 91 (1989).
   Google Scholar
• Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69(3), 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat. Med.13(11), 1359–1362 (2007).
   PubMed Web of Science ®Google Scholar
• Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov.2(7), 566–580 (2003).
   PubMed Web of Science ®Google Scholar